Pipeline
NovelWise is advancing a pipeline of specific HDAC inhibitors.
| Program | Discovery | Preclinical | Phase I | Phase Ib/Expansion | Phase II | Phase III |
|---|---|---|---|---|---|---|
| HDAC8 inhibitor (NBM-BMX) | ||||||
| Metastatic Uveal Melanoma | ||||||
| Glioblastoma | ||||||
| Hepatocellular Carcinoma：Investigator-Initiated Trial | ||||||
| Mesothelioma：Investigator-Initiated Trial | ||||||
| HDAC11 Inhibitor | ||||||
NBM-BMX – Mechanism of Action
NBM-BMX: Specific HDAC8 Inhibitor
- Oral, small-molecule epigenetic therapy
- Selectively targets HDAC8, reducing toxicity compared with first-generation HDAC inhibitors
Dual action
- Tumor growth inhibition (cell cycle arrest, apoptosis)
- Anti-angiogenesis (blocking VEGF signaling) Demonstrated efficacy in glioblastoma & uveal melanoma preclinical models
- NBM-BMX is being investigated as a potential therapy for patients with advanced solid tumors, glioblastoma, and metastatic uveal melanoma in ongoing Phase 1b/2 clinical trials.
- NBM-BMX has demonstrated selective inhibition of HDAC8 with dual anti-cancer activity, blocking tumor growth and angiogenesis.
Clinical program include:
- NBM-BMX-003 (TW): Phase 1b/2 trial in glioblastoma
- NBM-BMX-004 (US): Phase 1b/2 trial in metastatic uveal melanoma
Novelwise has submitted an application to the U.S. FDA for Orphan Drug Designation of NBM-BMX in uveal melanoma, marking an important step toward bringing new treatment options for patients with rare and hard-to-treat cancers.
Related Programs
Metastatic Uveal Melanoma
NBM-BMX: Metastatic Uveal Melanoma (Phase 1b/2)
Glioblastoma
NBM-BMX: Glioblastoma (TW, Phase 1b/Expansion → Phase 2)
Investigator-Initiated Trial
Hepatocellular Carcinoma：Investigator-Initiated Trial
Mesothelioma：Investigator-Initiated Trial